One weekly medication that works on two metabolic hormones—GLP-1 and GIP—prescribed and managed by licensed providers, entirely online.
The first weight-loss medication to activate both incretin receptors at once.
Tirzepatide activates two incretin receptors, curbing appetite while supporting the way your body handles energy.
Once weeklyIn the 72-week SURMOUNT-1 trial, adults on the highest dose lost about 20% of their body weight on average.
Doses climb gradually under provider control so side effects stay manageable.
Check-ins, habit coaching, and plan adjustments continue for as long as you are treated.
The stronger the therapy, the more supervision matters. HDMeds pairs tirzepatide with structured titration, side-effect coaching, and follow-ups that keep results on track.
Get Started
“HDMeds has been a game changer. The process was simple, the care is incredible, and I've lost over 32 lbs in 4 months. I finally feel like myself again!”
“HDMeds helped me optimize my health and energy. I feel better than I have in years.”
“After a few weeks, my skin looks brighter and my hair feels stronger. I love that my plan is personalized and shipped discreetly to my door.”
“HDMeds made it easy to get the help I needed. Professional, discreet, and effective.”
“HDMeds has been a game changer. The process was simple, the care is incredible, and I've lost over 32 lbs in 4 months. I finally feel like myself again!”
“HDMeds helped me optimize my health and energy. I feel better than I have in years.”
“After a few weeks, my skin looks brighter and my hair feels stronger. I love that my plan is personalized and shipped discreetly to my door.”
“HDMeds made it easy to get the help I needed. Professional, discreet, and effective.”
Tirzepatide is a dual GIP and GLP-1 receptor agonist—the active ingredient in Mounjaro® and Zepbound®. By activating two incretin hormone pathways at once, it reduces appetite and supports how your body manages energy.
In the SURMOUNT-1 clinical trial, adults on the highest dose lost about 20% of their body weight on average over 72 weeks—among the strongest results ever recorded for a weight-loss medication. Individual results vary with dose, consistency, and lifestyle.
In head-to-head research, tirzepatide produced greater average weight loss, but the better choice depends on your health history, tolerability, and goals. Your HDMeds provider will recommend the option that fits you—and can switch your plan later if needed.
Mostly digestive—nausea, decreased appetite, and occasional constipation or diarrhea—typically during the first weeks and after dose increases. Careful, provider-paced titration keeps most patients comfortable.
Complete a short intake, get reviewed by a U.S. licensed provider, and—if tirzepatide is appropriate—your medication ships cold-chain to your door with ongoing check-ins built in.
Dual-action tirzepatide therapy with provider supervision from first dose to goal.
